S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
S&P 500   4,286.76 (-0.03%)
DOW   33,403.12 (-0.31%)
QQQ   359.97 (+0.47%)
AAPL   173.04 (+1.07%)
MSFT   317.43 (+0.53%)
META   304.82 (+1.54%)
GOOGL   132.80 (+1.48%)
AMZN   128.21 (+0.86%)
TSLA   246.06 (-1.66%)
NVDA   446.38 (+2.62%)
NIO   8.80 (-2.65%)
BABA   86.27 (-0.54%)
AMD   103.31 (+0.48%)
T   14.95 (-0.47%)
F   12.38 (-0.32%)
MU   68.77 (+1.09%)
CGC   0.77 (-1.70%)
GE   110.18 (-0.33%)
DIS   80.91 (-0.17%)
AMC   8.33 (+4.26%)
PFE   33.37 (+0.60%)
PYPL   59.25 (+1.35%)
NFLX   380.49 (+0.77%)
NASDAQ:TNDM

Tandem Diabetes Care (TNDM) Stock Forecast, Price & News

$21.07
+0.30 (+1.44%)
(As of 09:57 AM ET)
Compare
Today's Range
$20.60
▼
$21.07
50-Day Range
$19.33
▼
$36.22
52-Week Range
$19.11
▼
$58.82
Volume
74,631 shs
Average Volume
1.29 million shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.80
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Tandem Diabetes Care MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
125.3% Upside
$46.80 Price Target
Short Interest
Bearish
12.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.64
Upright™ Environmental Score
News Sentiment
1.34mentions of Tandem Diabetes Care in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$21,450 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.49) to ($1.15) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

153rd out of 968 stocks

Surgical & Medical Instruments Industry

24th out of 101 stocks

See Top Rated MarketRank™ Stocks Here

TNDM stock logo

About Tandem Diabetes Care (NASDAQ:TNDM) Stock

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Price History

TNDM Stock News Headlines

September 29, 2023 | barrons.com
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm
September 29, 2023 | finance.yahoo.com
2 Stocks Under $25 to Buy and Hold for 10 Years
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 27, 2023 | benzinga.com
TNDM Investors Have Opportunity to Lead Tandem Diabetes Care, Inc. Securities Fraud Lawsuit
September 26, 2023 | gurufocus.com
Decoding Tandem Diabetes Care Inc (TNDM)'s Performance Potential: A Deep Dive into Key Metrics
September 26, 2023 | finance.yahoo.com
Investing in Tandem Diabetes Care (TNDM): Navigating the Thin Line Between Value and Trap
September 24, 2023 | stockhouse.com
TNDM INVESTOR NOTICE: Tandem Diabetes Care, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 24, 2023 | americanbankingnews.com
Tandem Diabetes Care (NASDAQ:TNDM) Reaches New 12-Month Low at $20.64
October 2, 2023 | Wall Street Fundamentals (Ad)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
September 22, 2023 | benzinga.com
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Tandem Diabetes Care, Inc. (TNDM)
September 21, 2023 | benzinga.com
TNDM Shareholder Alert: Investors with Large Losses Should Contact Robbins LLP for Information About Recovery Against Tandem Diabetes Care, Inc.
September 19, 2023 | businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) Investors
September 18, 2023 | technews.tmcnet.com
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Tandem Diabetes Care, Inc. (TNDM) Investors
September 15, 2023 | tmcnet.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors
September 15, 2023 | benzinga.com
Tandem Diabetes Care, Inc. (TNDM) Investor Alert: Robbins LLP Reminds Investors of Class Action Filed Against Tandem Diabetes Care, Inc.
September 15, 2023 | finance.yahoo.com
Unraveling the Future of Tandem Diabetes Care Inc (TNDM): A Deep Dive into Key Metrics
September 15, 2023 | businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors
September 14, 2023 | businesswire.com
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors
September 13, 2023 | benzinga.com
The Law Offices of Frank R. Cruz Announces Investigation of Tandem Diabetes Care, Inc. (TNDM) on Behalf of Investors
September 13, 2023 | stockhouse.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Tandem Diabetes Care, Inc. with Losses of $100,000 to Contact the Firm
September 13, 2023 | benzinga.com
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Tandem Diabetes Care, Inc. (TNDM)
September 13, 2023 | businesswire.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TNDM
September 11, 2023 | technews.tmcnet.com
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Tandem Diabetes Care, Inc.
September 8, 2023 | cnbc.com
Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
September 7, 2023 | msn.com
Insulet, Tandem Diabetes drop as weight loss drugs impact insulin use
September 7, 2023 | finance.yahoo.com
Is Tandem Diabetes Care (TNDM) Too Good to Be True? A Comprehensive Analysis of a Potential ...
September 7, 2023 | finance.yahoo.com
Is Tandem Diabetes Care Inc (TNDM) Set to Underperform? Analyzing the Factors Limiting Growth
See More Headlines
Receive TNDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.

TNDM Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
CUSIP
N/A
CIK
1438133
Web
www.tandemdiabetes.com
Phone
(858) 366-6900
Fax
N/A
Employees
2,600
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$46.80
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+125.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-94,590,000.00
Net Margins
-28.40%
Pretax Margin
-28.05%
Return on Equity
-20.29%
Return on Assets
-7.76%

Debt

Debt-to-Equity Ratio
0.86
Current Ratio
4.38
Quick Ratio
3.53

Sales & Book Value

Annual Sales
$790.35 million
Price / Sales
1.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.84 per share
Price / Book
3.04

Miscellaneous

Outstanding Shares
65,078,000
Free Float
63,451,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.87

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. John F. SheridanMr. John F. Sheridan (Age 68)
    Pres, CEO & Director
    Comp: $1.23M
  • Ms. Leigh A. VossellerMs. Leigh A. Vosseller (Age 50)
    Exec. VP, CFO & Treasurer
    Comp: $665.43k
  • Mr. David B. Berger Esq. (Age 53)
    Exec. VP & COO
    Comp: $670.18k
  • Ms. Susan M. MorrisonMs. Susan M. Morrison (Age 44)
    Exec. VP & Chief Admin. Officer
    Comp: $674.76k
  • Mr. Brian B. HansenMr. Brian B. Hansen (Age 55)
    Exec. VP & Chief Commercial Officer
    Comp: $650.19k
  • Ms. Elizabeth Anne GasserMs. Elizabeth Anne Gasser (Age 46)
    Exec. VP & Chief Strategy Officer
    Comp: $606.83k
  • Mr. Rick A. Carpenter (Age 60)
    Chief Technical Officer
  • Ms. Shannon M. Hansen (Age 57)
    Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. Ross Sylvia
    VP of Marketing
  • Mr. Tom Fox
    Sr. VP of HR & Organizational Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TNDM Stock - Frequently Asked Questions

Should I buy or sell Tandem Diabetes Care stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TNDM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TNDM, but not buy additional shares or sell existing shares.
View TNDM analyst ratings or view top-rated stocks.

What is Tandem Diabetes Care's stock price forecast for 2023?

12 brokerages have issued twelve-month price objectives for Tandem Diabetes Care's shares. Their TNDM share price forecasts range from $30.00 to $75.00. On average, they expect the company's stock price to reach $46.80 in the next year. This suggests a possible upside of 125.3% from the stock's current price.
View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts.

How have TNDM shares performed in 2023?

Tandem Diabetes Care's stock was trading at $44.95 at the beginning of the year. Since then, TNDM shares have decreased by 53.8% and is now trading at $20.77.
View the best growth stocks for 2023 here.

When is Tandem Diabetes Care's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our TNDM earnings forecast.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its earnings results on Thursday, August, 3rd. The medical device company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.24. The medical device company earned $195.92 million during the quarter, compared to analyst estimates of $201.62 million. Tandem Diabetes Care had a negative trailing twelve-month return on equity of 20.29% and a negative net margin of 28.40%.

What ETFs hold Tandem Diabetes Care's stock?

ETFs with the largest weight of Tandem Diabetes Care (NASDAQ:TNDM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Harbor Corporate Culture Small Cap ETF (HAPS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Syntax Stratified SmallCap ETF (SSLY).iShares U.S. Medical Devices ETF (IHI).

When did Tandem Diabetes Care's stock split?

Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $785.00M-, compared to the consensus revenue estimate of $881.47 million.

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $20.77.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $1.35 billion and generates $790.35 million in revenue each year. The medical device company earns $-94,590,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

The company employs 2,600 workers across the globe.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com.

This page (NASDAQ:TNDM) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -